Compugen (CGEN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Compugen stock (CGEN) is currently trading at $2.07. Compugen PE ratio is 5.50. Compugen PS ratio (Price-to-Sales) is 2.73. Analyst consensus price target for CGEN is $5.80. WallStSmart rates CGEN as Moderate Buy.
- CGEN PE ratio analysis and historical PE chart
- CGEN PS ratio (Price-to-Sales) history and trend
- CGEN intrinsic value — DCF, Graham Number, EPV models
- CGEN stock price prediction 2025 2026 2027 2028 2029 2030
- CGEN fair value vs current price
- CGEN insider transactions and insider buying
- Is CGEN undervalued or overvalued?
- Compugen financial analysis — revenue, earnings, cash flow
- CGEN Piotroski F-Score and Altman Z-Score
- CGEN analyst price target and Smart Rating
Compugen
📊 No data available
Try selecting a different time range
CGEN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Compugen (CGEN)
CGEN trades at a significant discount to its Graham intrinsic value of $2.58, offering a 34% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Compugen (CGEN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, operating margin. Concerns around market cap and institutional own.. Overall metrics suggest strong investment potential with favorable risk/reward.
Compugen (CGEN) Key Strengths (6)
Every $100 of shareholder equity generates $45 in profit
Keeps $83 of every $100 in revenue after operating costs
Revenue surging 4477.00% year-over-year
Keeps $49 of every $100 in revenue as net profit
Good growth relative to its price
Trading at 1.92x book value, attractively priced
Supporting Valuation Data
Compugen (CGEN) Areas to Watch (3)
Very low institutional interest at 13.55%
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.73x sales
Compugen (CGEN) Detailed Analysis Report
Overall Assessment
This company scores 69/100 in our Smart Analysis, earning a B- grade. Out of 9 metrics analyzed, 6 register as strengths (avg 9.3/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Revenue Growth. Valuation metrics including PEG Ratio (1.29), Price/Book (1.92) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 44.80%, Operating Margin at 83.20%, Profit Margin at 48.60%. Growth metrics are encouraging with Revenue Growth at 4477.00%.
The Bear Case
The primary concerns are Institutional Own., Market Cap, Price/Sales. Some valuation metrics including Price/Sales (2.73) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Institutional Own. improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 44.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 4477.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Institutional Own., Market Cap). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CGEN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CGEN's Price-to-Sales ratio of 2.73x trades at a deep discount to its historical average of 659.51x (1th percentile). The current valuation is 100% below its historical high of 4015.82x set in Nov 2013, and 1% above its historical low of 2.69x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~24.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Compugen (CGEN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Compugen is a strong growth company balancing expansion with improving profitability. Revenue reached 73M with 4477% growth year-over-year. Profit margins are strong at 48.6%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 4477% YoY, reaching 73M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 4480.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Compugen maintain 4477%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.96, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Compugen.
Bottom Line
Compugen offers an attractive blend of growth (4477% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:28:17 AM
About Compugen(CGEN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.